Acrivon Therapeutics, Inc.
ACRV
$1.48
-$0.16-9.76%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.76% | -2.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.74% | 17.27% | |||
| Operating Income | 0.74% | -17.27% | |||
| Income Before Tax | -1.74% | -19.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.74% | -19.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.74% | -19.38% | |||
| EBIT | 0.74% | -17.27% | |||
| EBITDA | 0.96% | -17.35% | |||
| EPS Basic | -1.38% | -13.18% | |||
| Normalized Basic EPS | -5.35% | -13.19% | |||
| EPS Diluted | -1.38% | -13.18% | |||
| Normalized Diluted EPS | -5.35% | -13.19% | |||
| Average Basic Shares Outstanding | 0.36% | 5.46% | |||
| Average Diluted Shares Outstanding | 0.36% | 5.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
